ArticleMolecular therapy. Oncology2025
Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers.
Tina Briolay et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it